Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability.

Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.

J Med Chem. 2018 Feb 8;61(3):1153-1163. doi: 10.1021/acs.jmedchem.7b01630. Epub 2018 Jan 25.

PMID:
29342358
2.

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C.

Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11. doi: 10.1128/AAC.04619-14. Epub 2014 Dec 22.

3.

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T.

Antimicrob Agents Chemother. 2015 Feb;59(2):979-87. doi: 10.1128/AAC.04226-14. Epub 2014 Dec 1.

4.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM.

J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15.

PMID:
24400777
5.

High potency improvements to weak aryl uracil HCV polymerase inhibitor leads.

Donner P, Randolph JT, Huang P, Wagner R, Maring C, Lim BH, Colletti L, Liu Y, Mondal R, Beyer J, Koev G, Marsh K, Beno D, Longenecker K, Pilot-Matias T, Kati W, Molla A, Kempf D.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4367-9. doi: 10.1016/j.bmcl.2013.05.078. Epub 2013 Jun 4.

PMID:
23791079
6.

Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3487-90. doi: 10.1016/j.bmcl.2013.04.057. Epub 2013 May 1.

PMID:
23664214
7.

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B.

J Hepatol. 2013 Jul;59(1):18-23. doi: 10.1016/j.jhep.2013.02.009. Epub 2013 Feb 22.

PMID:
23439262
8.

Exploratory study of oral combination antiviral therapy for hepatitis C.

Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B.

N Engl J Med. 2013 Jan 3;368(1):45-53. doi: 10.1056/NEJMoa1208809.

9.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

Hutchinson DK, Flentge CA, Donner PL, Wagner R, Maring CJ, Kati WM, Liu Y, Masse SV, Middleton T, Mo H, Montgomery D, Jiang WW, Koev G, Beno DW, Stewart KD, Stoll VS, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1876-9. doi: 10.1016/j.bmcl.2010.12.067. Epub 2011 Jan 13.

PMID:
21316235
10.

Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.

Randolph JT, Flentge CA, Huang PP, Hutchinson DK, Klein LL, Lim HB, Mondal R, Reisch T, Montgomery DA, Jiang WW, Masse SV, Hernandez LE, Henry RF, Liu Y, Koev G, Kati WM, Stewart KD, Beno DW, Molla A, Kempf DJ.

J Med Chem. 2009 May 28;52(10):3174-83. doi: 10.1021/jm801485z.

PMID:
19402666
11.

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.

Wagner R, Larson DP, Beno DW, Bosse TD, Darbyshire JF, Gao Y, Gates BD, He W, Henry RF, Hernandez LE, Hutchinson DK, Jiang WW, Kati WM, Klein LL, Koev G, Kohlbrenner W, Krueger AC, Liu J, Liu Y, Long MA, Maring CJ, Masse SV, Middleton T, Montgomery DA, Pratt JK, Stuart P, Molla A, Kempf DJ.

J Med Chem. 2009 Mar 26;52(6):1659-69. doi: 10.1021/jm8010965.

PMID:
19226162
12.

Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.

Mondal R, Koev G, Pilot-Matias T, He Y, Ng T, Kati W, Molla A.

Antiviral Res. 2009 Apr;82(1):82-8. doi: 10.1016/j.antiviral.2008.12.012. Epub 2009 Jan 25.

PMID:
19174175
13.

Extreme Reduction of Disease in Oats Transformed with the 5' Half of the Barley Yellow Dwarf Virus-PAV Genome.

Koev G, Mohan BR, Dinesh-Kumar SP, Torbert KA, Somers DA, Miller WA.

Phytopathology. 1998 Oct;88(10):1013-9. doi: 10.1094/PHYTO.1998.88.10.1013.

14.

Methods to measure the intracellular concentration of unlabeled compounds within cultured cells using liquid chromatography/tandem mass spectrometry.

Colletti LM, Liu Y, Koev G, Richardson PL, Chen CM, Kati W.

Anal Biochem. 2008 Dec 15;383(2):186-93. doi: 10.1016/j.ab.2008.08.012. Epub 2008 Aug 22.

PMID:
18790690
15.

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.

Donner PL, Xie Q, Pratt JK, Maring CJ, Kati W, Jiang W, Liu Y, Koev G, Masse S, Montgomery D, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2735-8. doi: 10.1016/j.bmcl.2008.02.064. Epub 2008 Mar 4.

PMID:
18362072
16.

The emerging field of HCV drug resistance.

Koev G, Kati W.

Expert Opin Investig Drugs. 2008 Mar;17(3):303-19. doi: 10.1517/13543784.17.3.303 . Review.

PMID:
18321230
17.

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.

Bosse TD, Larson DP, Wagner R, Hutchinson DK, Rockway TW, Kati WM, Liu Y, Masse S, Middleton T, Mo H, Montgomery D, Jiang W, Koev G, Kempf DJ, Molla A.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):568-70. Epub 2007 Nov 28.

PMID:
18068361
18.

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

Middleton T, He Y, Pilot-Matias T, Tripathi R, Lim BH, Roth A, Chen CM, Koev G, Ng TI, Krishnan P, Pithawalla R, Mondal R, Dekhtyar T, Lu L, Mo H, Kati WM, Molla A.

J Virol Methods. 2007 Nov;145(2):137-45. Epub 2007 Jun 29.

PMID:
17604129
19.

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Masse S, Lu X, Dekhtyar T, Lu L, Koev G, Gao F, Mo H, Kempf D, Bernstein B, Hanna GJ, Molla A.

Antimicrob Agents Chemother. 2007 Sep;51(9):3075-80. Epub 2007 Jun 18.

20.

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.

Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, Ng T, Koev G, Stewart K, Larson D, Bosse T, Wagner R, Pilot-Matias T, Mo H, Molla A.

Antiviral Res. 2007 Oct;76(1):93-7. Epub 2007 May 22.

PMID:
17561278
21.

Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology.

Ng TI, Mo H, Pilot-Matias T, He Y, Koev G, Krishnan P, Mondal R, Pithawalla R, He W, Dekhtyar T, Packer J, Schurdak M, Molla A.

Hepatology. 2007 Jun;45(6):1413-21.

PMID:
17518369
22.

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.

Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A.

Antiviral Res. 2007 Jan;73(1):78-83. Epub 2006 Aug 17.

PMID:
16945431
23.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A.

Antimicrob Agents Chemother. 2005 Oct;49(10):4305-14.

26.

Synthesis of subgenomic RNAs by positive-strand RNA viruses.

Miller WA, Koev G.

Virology. 2000 Jul 20;273(1):1-8. Review. No abstract available.

27.
28.
29.

Getting a handle on RNA virus recombination.

Miller WA, Koev G.

Trends Microbiol. 1998 Nov;6(11):421-3. Review. No abstract available.

PMID:
9846351
30.

Are There Risks Associated with Transgenic Resistance to Luteoviruses?

Miller WA, Koev G, Mohan BR.

Plant Dis. 1997 Jul;81(7):700-710. doi: 10.1094/PDIS.1997.81.7.700. No abstract available.

PMID:
30861876

Supplemental Content

Support Center